388 related articles for article (PubMed ID: 36059451)
21. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
22. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
23. Research Techniques Made Simple: CAR T-Cell Therapy.
Siddiqi HF; Staser KW; Nambudiri VE
J Invest Dermatol; 2018 Dec; 138(12):2501-2504.e1. PubMed ID: 30243656
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
Khurana A; Lin Y
Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
[TBL] [Abstract][Full Text] [Related]
27. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
Weiner DM; Durgin JS; Wysocka M; Rook AH
J Am Acad Dermatol; 2021 Mar; 84(3):597-604. PubMed ID: 33352268
[TBL] [Abstract][Full Text] [Related]
28. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
Sun W; Jiang Z; Jiang W; Yang R
Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
[TBL] [Abstract][Full Text] [Related]
29. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
Watanabe K; Gomez AM; Kuramitsu S; Siurala M; Da T; Agarwal S; Song D; Scholler J; Rotolo A; Posey AD; Rook AH; Haun PL; Ruella M; Young RM; June CH
Blood Adv; 2023 Jul; 7(14):3416-3430. PubMed ID: 37058474
[TBL] [Abstract][Full Text] [Related]
30. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
31. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
32. CAR-Based Approaches to Cutaneous T-Cell Lymphoma.
Scarfò I; Frigault MJ; Maus MV
Front Oncol; 2019; 9():259. PubMed ID: 31058076
[TBL] [Abstract][Full Text] [Related]
33. Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.
Guo S; Gao X; Sadhana M; Guo R; Liu J; Lu W; Zhao MF
Curr Treat Options Oncol; 2023 Nov; 24(11):1614-1632. PubMed ID: 37870695
[TBL] [Abstract][Full Text] [Related]
34. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
Zhang C; Zhuang Q; Liu J; Liu X
ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
[TBL] [Abstract][Full Text] [Related]
35. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
37. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T cell: A cancer immunotherapy.
Singh S; Khasbage S; Kaur RJ; Sidhu JK; Bhandari B
Indian J Pharmacol; 2022; 54(3):226-233. PubMed ID: 35848695
[TBL] [Abstract][Full Text] [Related]
39. Bispecific CAR T-cells for B-cell Malignancies.
Furqan F; Shah NN
Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
[TBL] [Abstract][Full Text] [Related]
40. Engineering strategies to overcome the current roadblocks in CAR T cell therapy.
Rafiq S; Hackett CS; Brentjens RJ
Nat Rev Clin Oncol; 2020 Mar; 17(3):147-167. PubMed ID: 31848460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
